Form 8-K Processa Pharmaceuticals For: May 16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) |
(I.R.S.
Employer Identification No.) |
(Address of Principal Executive Office) |
(Zip Code) |
Registrant’s
telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol | Name of Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
Processa Pharmaceuticals, Inc. (the “Company”) is filing this Form 8-K to provide current information regarding its patent portfolio and to correct prior disclosures regarding the number of U.S. patents licensed from Elion. Accordingly, in addition to the international patents and/or international and U.S. patent applications licensed from third-party licensors, the Company currently licenses at least the following number of U.S. patents:
CONCERT | Yuhan | Aposense | Elion | Ocuphire | Total | |||||||||||||
U.S. Patents | 9 | 4 | 3 | 2 | 6 | 24 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROCESSA PHARMACEUTICALS, INC. | |||
/s/ David Young | |||
Date: | May 16, 2022 | David Young | |
Chief Executive Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
- NHOA Group: New Partnership Emil Frey France x Atlante France, About Fifteen Fastcharging Stations for the Autosphere Dealerships
- Sovos and PwC in Belgium Establish Joint Business Relationship to Accelerate e-Invoicing Implementation
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!